EMA Authorised: Rivastigmine 1 A Pharma (rivastigmine) — 1 A Pharma GmbH

View source ↗

Summary

The EMA authorised rivastigmine from 1 A Pharma GmbH for use in Alzheimer's disease, dementia, and Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Parkinson Disease

Drugs mentioned

• Rivastigmine (Rivastigmine)

Snippet

Status: Authorised. Therapeutic area: Alzheimer Disease;Dementia;Parkinson Disease. MAH: 1 A Pharma GmbH. Decision date: 15/01/2026